

Early Detection and Targeted Treatments investments – 20/21 to 25/26

2025 Round 2	<ul style="list-style-type: none"> Improving the iDentification of people at risk of developing rheumatoid Arthritis in primary care (IDEAS-PC intervention) through targeted anti-CCP testing: understanding rheumatologists' perspectives Impact of systemic factors on tendon health in the context of exercise, disease and nutritional supplementation: towards avenues for improved diagnosis and treatment Development of an ROS/RNS sensor for the early detection of osteoarthritis LEARNING from Flare biology to develop biomarkers for imminent and Early RA (LEAF-ERA) Signatures of Risk in RA: the SORIRA study Raman Glycoprofiling of Arthritic Heterogeneity A Randomised COntrolled tRial of aDalimumab versus Pamidronate in chronIc NonbacteriAl osTeomyelitis (CNO) using BayEsian Design – COORDINATED (<i>co-funded with NIHR HTA programme</i>)
2025	<ul style="list-style-type: none"> Translating genetic discoveries to improve the accuracy of predicting cardiovascular outcomes in patients with rheumatic musculoskeletal diseases [Read more] Recalibration of cardiovascular risk prediction tools to improve the prediction of cardiovascular diseases and provide better access to preventive measures for people with gout [Read more] Stratification of disease progression To Enable Personalized medicine For people With earlier-stage knee osteoarthritis (STEP FORWARD) [Read more] Identification of patients at risk of OA who will benefit from Agrin treatment [Read more] Therapeutic tissue RESET through targeted fibroblast depletion in arthritis [Read more] Peptide-siRNA conjugates: A novel targeted therapeutic approach for the treatment of chronic inflammation and pain in osteoarthritic joints [Read more] Role of cGAS-STING/IFN-I pathway in the establishment of synovial B-cells niches and response to B-cell depleting therapies in rheumatoid arthritis [Read more] Active UCHL1 and a DUB trio signature as prognostic biomarkers for early detection, severity assessment, and targeted therapy in traumatic osteoarthritis [Read more]
2024	<ul style="list-style-type: none"> Targeting Cellular Senescence to combat osteoarthritis and related conditions [Read more] Intestinal permeability – a new target for autoimmune diseases prevention and therapy [Read more] BAR-JDM: Baricitinib in Juvenile Dermatomyositis: multi-centre open label, superiority trial [Read more] Identifying synovial tissue biomarkers and mechanisms of transition from pre-clinical RA to RA [Read more] A randomised biomarker enrichment trial: IgA2 anti-DNA antibodies as a biomarker of response to belimumab after rituximab in systemic lupus erythematosus - STRATIFY lupus (<i>co-funded with NIHR EME programme</i>) [Read more] PrIoritising early detection of KNEE osteoaRthritis – P1OKNEER [Read more] How do people develop SLE and can this be prevented? [Read more]
2023	<ul style="list-style-type: none"> Identifying molecular mechanisms underlying pain relief response to physiotherapy in people with osteoarthritis Assessing central nervous system contributions to accelerate musculoskeletal pain diagnosis and treatment (CNS-MSK Pain) Early detection of severe disease in Juvenile Idiopathic Arthritis Defining renal pathotypes in ANCA-associated vasculitis to improve treatment stratification RESOLVE: towards early, targeted restoration of immune resolution in RA Treg Fitness As Biomarker For Disease Activity To Predict Treatment Response In JIA Identifying the dietary signatures of arthritis through metabolomics (the DESIGNA study)

-
- | | |
|------|---|
| 2022 | <ul style="list-style-type: none">• IgA2 anti-DNA antibodies as a biomarker of organ involvement and response to belimumab after rituximab in systemic lupus erythematosus• Assessing whole body synovial inflammation as a predictor of flare when tapering therapy in rheumatoid arthritis• A randomised feasibility study to evaluate home-based personalised virtual reality physiotherapy rehabilitation compared to usual care in the treatment of pain for people with knee osteoarthritis |
| 2021 | <ul style="list-style-type: none">• Immune cell profiling in the preclinical phase of rheumatoid arthritis• Accelerating New Treatments for Refractory RA through targeting the FGF Family• Treating axial spondyloarthritis via the gut microbiome• Defining the cellular basis of disease persistence in Juvenile Idiopathic Arthritis |
-